News
Company News: Cardior Pharmaceuticals Demonstrates Reversal of Cardiac Hypertrophy by H19 Gene Therapy
— Administration of AAV9 expressing H19 attenuates cardiac hypertrophy in vivo and prevents progression to heart failure
— Details on novel mechanism of action published in peer-reviewed study in the European Heart Journal
Cardior Pharmaceuticals GmbH, a clinical-stage biotech company focused on the development of noncoding RNA (ncRNA) therapeutics for patients with cardiovascular diseases, today announced the results of extensive in vitro and in vivo studies demonstrating the therapeutic potential of H19 gene therapy to combat cardiac hypertrophy and heart failure. Read more…
Company News: Anergis and Virometix Announce Research Collaboration to Use Synthetic Virus-Like Particles for Ultra-Fast Allergy Immunotherapy
— Study is performed at the Helmholtz Centre for Infection Research and supported by a TRANSVAC2 grant
Anergis SA, a company developing Contiguous Overlapping Peptides (COPs) for ultra-fast allergy immunotherapy, and Virometix AG, a company developing a new generation of vaccines and immunotherapeutic drugs, announced today that they have entered into a research collaboration. Read more…
German Corona Showcase, June 23-25, 2020
Watch out for the upcoming virtual German Corona Showcase!
akampion´s Ludger Wess will be chairing a session on June 25, 2020, starting at 12:50pm CET:
“How are the companies doing that are not working on the corona virus? How is the pandemic affecting their businesses?”
Heraeus Medical to Host Interactive Webinar “Orthopedic Surgery in COVID-19 Times”
Orthopedic surgery in COVID-19 times
To educate surgical teams in the management of periprosthetic joint infections in pandemic times, the PALACADEMY® of Heraeus Medical has expanded it virtual program. Teams are now invited to take part in the first interactive webinar
“Periprosthetic joint infections in pandemic times. Focus on risk patients and prevention.”